Publications by authors named "Sophie P Shaw"
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Bryan Smith Andrea Kiessling Rocio Lledo-Garcia Kate L Dixon Louis Christodoulou Sophie P Shaw Stevan Shaw
MAbs
October 2018
Article Synopsis
- Rozanolixizumab (UCB7665) is a monoclonal antibody designed to target and reduce harmful IgG antibodies in autoimmune and alloimmune diseases by inhibiting the neonatal Fc receptor (FcRn).
- Studies show that this antibody effectively lowers plasma IgG levels in animal models (mice and cynomolgus monkeys) without affecting albumin levels and demonstrates a good safety profile during prolonged administration.
- Current research includes clinical trials for conditions like immune thrombocytopenia and myasthenia gravis, suggesting rozanolixizumab could be a promising new treatment option for these diseases.
Single B cell technologies, which avoid traditional hybridoma fusion and combinatorial display, provide a means to interrogate the naturally-selected antibody repertoire of immunized animals. Many methods enable the sampling of memory B cell subsets, but few allow for the direct interrogation of the plasma cell repertoire, i.e.
View Article and Find Full Text PDF